AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30021691
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of montelukast/levocetirizine 10/5 mg
Trial: 30021691
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of montelukast and levocetirizine
Trial: 27180088
Drug: Patient navigation
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient navigation plus medications
Trial: 25223180
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (mainly by GC and cyclophosphamide)
Trial: 8560598
Drug: R‐ORS (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R‐ORS (50 g/L)
Trial: 1537131
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2.7 g/day of eicosapentaenoic acid, 1.8 g/day of docosahexaenoic acid)
Trial: 1537131
Drug: Dietary intake
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intake of omega-3 fatty acids > 0.15 g/day
Trial: 27622998
Drug: Diuretic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic therapy (DT) with midodrine and rifaximin (n=400)
Trial: 27622998
Drug: Diuretic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic therapy (DT) only (n=200)
Trial: 22632139
Drug: Telephone-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based intervention consisting of four sessions of motivational interviewing (MI) and cognitive behavioural therapy (CBT)
Trial: 19361872
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (40 mg administered three times daily)
Trial: 2625616
Drug: Phenylephrine HCl
RxNorm normalized name: Phenylephrine HCl
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine HCl 5%-tropicamide 0.8% combination mydriatic (Phenyltrope)
Trial: 857369
Drug: Dextran 70
RxNorm normalized name: Dextran 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 70 (2 X 500 ml i.v.)
Trial: 28592037
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii 500 mg twice a day for 21 days
Trial: 26288285
Drug: APTPA (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APTPA (500 mg glucosamine hydrochloride and 500 mg chondroitin sulfate) + melaxen (3 mg melatonin 30-40 min before sleep)
Trial: 26288285
Drug: APTPA (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APTPA (1 tablet twice a day) + melaxen (3 mg melatonin 30-40 min before sleep)
Trial: 26288285
Drug: APTPA (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APTPA (1 tablet twice a day) + diclofenac (25 mg 2-3 times a day) + melaxen (3 mg melatonin 30-40 min before sleep)
Trial: 26288285
Drug: APTPA (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APTPA (1 tablet twice a day) + diclofenac (25 mg 2-3 times a day)
Trial: 26288285
Drug: APTPA (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APTPA (1 tablet twice a day) + diclofenac (25 mg 2-3 times a day) without melaxen
Trial: 21396091
Drug: Clotrimazole vaginal
RxNorm normalized name: Clotrimazole Vaginal Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole vaginal pessaries (100 mg) for 6 days
Trial: 21396091
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (no treatment, routine antenatal care)
Trial: 18287162
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with 1 g sachets of HR (2 g/d total) plus topical HR 2% gel applied 3 times daily at the internal perimalleolar region
Trial: 18287162
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment only (same dosage)
Trial: 18287162
Drug: Healthy individuals
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy individuals without treatment (control group)
Trial: 3512619
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin 0.5 mg/kg/d
Trial: 3512619
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin 15 mg/kg/d
Trial: 3512619
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin 0.5 mg/kg/d and 15 mg/kg/d
Trial: 27538952
Drug: Xinyue capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinyue capsules (1.8 g/day, three times daily for up to 24 weeks)
Trial: 27538952
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (three times daily for up to 24 weeks)
Trial: 25431770
Drug: 8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g/day essential amino acids (EAAs); n=19
Trial: 17449306
Drug: Neramexane (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neramexane (40 mg p.o.)
Trial: 17449306
Drug: Flupirtine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine (100 mg)
Trial: 15946202
Drug: Prophylactic doses
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic doses of nadroparin (2850 a‐Xa IU)
Trial: 15946202
Drug: Therapeutic doses
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic doses of nadroparin (body-weight adjusted)
Trial: 12891111
Drug: Self-administered WIQ
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered WIQ
Trial: 12891111
Drug: Telephone-administered WIQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered WIQ
Trial: 10335905
Drug: (S)-propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)-propranolol 40 mg
Trial: 10335905
Drug: (R)-propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-propranolol 40 mg
Trial: 10335905
Drug: (R,S)-carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R,S)-carvedilol 25 mg
Trial: 10335905
Drug: (R,S)-verapamil 120
RxNorm normalized name: verapamil hydrochloride 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R,S)-verapamil 120 mg
Trial: 8724530
Drug: Amsacrine (AMSA)
RxNorm normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amsacrine (AMSA) 75 mg/m2/day x 4 plus continuous infusion high-dose cytarabine (CIHDAC) 1.5 g/m2/day x 4
Trial: 8724530
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion high-dose cytarabine (CIHDAC) alone
Trial: 16266472
Drug: Indapamide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (2.5 mg per day)
Trial: 6137327
Drug: Indapamide (used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (used alone or in combination)
Trial: 31821355
Drug: 0.8% hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8% hylan G-F 20 (control)
Trial: 29916110
Drug: Intravenous carbetocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous carbetocin (100 mcg)
Trial: 29916110
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (5 U)
Trial: 24769332
Drug: AXT914 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXT914 45 mg
Trial: 24769332
Drug: AXT914 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXT914 60 mg
Trial: 24769332
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 μg Forteo/PTH(1-34) fragment)
Trial: 21701082
Drug: Cilostazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (200 mg daily, n=24)
Trial: 21701082
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg daily, n=25)
Trial: 19493295
Drug: Internet-based sex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based sex therapy
Trial: 17470830
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg of body weight)
Trial: 7834003
Drug: 5-mL saline
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-mL saline instillation
Trial: 29915435
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention using wearable monitoring devices with IoT systems and monthly remote health guidance from a public health nurse.
Trial: 12620952
Drug: Bronchodilator premedication
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator premedication (albuterol or ipratropium)
Trial: 10695689
Drug: Low-dose antihypertensive
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose antihypertensive therapy
Trial: 8461472
Drug: 7 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g/d of a 85% omega-3 fatty acid fish oil concentrate
Trial: 3026009
Drug: Sulbactam/ampicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbactam/ampicillin (1 g of sulbactam and 2 g of ampicillin three times a day for two weeks)
Trial: 3026009
Drug: Cefotaxime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (2 g three times a day for two weeks)
Trial: 20422202
Drug: Compound Imaging
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Imaging (CI)
Trial: 20422202
Drug: Tissue Harmonic
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue Harmonic Compound Imaging (THICI)
Trial: 19075138
Drug: Dapsone gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone gel, 5%
Trial: 12460519
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormones (rhGH) 9 U/d
Trial: 7700763
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg/day intravenously for 3 days, 0.25 mg/kg/day for 3 days, and 0.1 mg/kg/day for 1 day)
Trial: 2199618
Drug: Chemotherapy (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (six IV cyclophosphamide, methotrexate, and fluorouracil courses followed by four IV epirubicin courses)
Trial: 18028017
Drug: Tamoxifen (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (5 years treatment)
Trial: 8740786
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus Tamoxifen
Trial: 2199618
Drug: Chemotherapy (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (with or without tamoxifen)
Trial: 21561896
Drug: GLP‐1 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP‐1 infusion
Trial: 28374695
Drug: Cytoflavin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin 10 ml/day
Trial: 28374695
Drug: Cytoflavin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin 20 ml/day
Trial: 25888067
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of docetaxel + sunitinib
Trial: 16042327
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (GHTX)
Trial: 16042327
Drug: Non-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment group (NonTX)
Trial: 12476037
Drug: 800-mg oral
RxNorm normalized name: piracetam 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800-mg oral dose of telithromycin
Trial: 12476037
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 400 mg telithromycin (young) or 480 mg telithromycin (elderly)
Trial: 10731130
Drug: Tazarotene plus
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene plus mid- or high-potency topical corticosteroid
Trial: 10731130
Drug: Tazarotene alternating
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene alternating with high-potency topical corticosteroid
Trial: 6892711
Drug: Free milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free milk supplement (190 ml daily for six school terms)
Trial: 31434111
Drug: Active homeopathic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active homeopathic medicine
Trial: 9649059
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of LMW heparin (nadroparin) 12,500 ICU AXa at the beginning of dialysis
Trial: 9649059
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of nadroparin 10,000 ICU AXa at the beginning of dialysis followed by a supplementary dose of nadroparin 2,500 ICU AXa at the beginning of the fifth hour of dialysis
Trial: 7521582
Drug: Aprotinin in
RxNorm normalized name: aprotinin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin in standard doses
Trial: 2672492
Drug: Diazemuls (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazemuls (10 mg)
Trial: 2672492
Drug: Valium Mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valium Mixed Micelles (10 mg)
Trial: 23891702
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone (CRH) 0.5μg/(kg body weight) intravenously administered for 24h
Trial: 21716251
Drug: Neyromidin (ipidacrinum)
RxNorm normalized name: ipidacrine
DrugBank: Ipidacrine (DB13668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neyromidin (ipidacrinum) used in intramuscular injections
Trial: 21716251
Drug: Neyromidin (ipidacrinum)
RxNorm normalized name: ipidacrine
DrugBank: Ipidacrine (DB13668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neyromidin (ipidacrinum) introduced by local injection perineural therapy
Trial: 19701041
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of re‐treatment
Trial: 19701041
Drug: Overall improvement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall improvement and treatment success rating
Trial: 14647880
Drug: 17beta‐estradiol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta‐estradiol 150 micro g
Trial: 14647880
Drug: 17beta‐estradiol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta‐estradiol 300 micro g
Trial: 11721100
Drug: Tirofiban (body-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban (body-weight adjusted intravenous) for a mean period of 46 hours
Trial: 8334344
Drug: Verapamil plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil plus Renal Disease Basic-prescription (RDBP)
Trial: 3557792
Drug: Rifampicin in
RxNorm normalized name: Product containing rifampicin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin in combination with isoniazid
Trial: 28470563
Drug: Qishen Yiqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishen Yiqi Dripping Pills (QSYQ)
Trial: 28470563
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (regular medication only)
Trial: 22626580
Drug: elocalcitol 75
RxNorm normalized name: Elocalcitol
DrugBank: Elocalcitol (DB06194)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elocalcitol 75 μg/d
Trial: 22626580
Drug: elocalcitol 150
RxNorm normalized name: Elocalcitol
DrugBank: Elocalcitol (DB06194)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elocalcitol 150 μg/d
Trial: 20838991
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg once daily for PMs
Trial: 12932668
Drug: Concomitant alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant alternating chemotherapy and radiation at the coordinating centre
Trial: 12932668
Drug: Concomitant alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant alternating chemotherapy and radiation at the affiliated centres
Trial: 11916762
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (60 mg Fe/d, 4 d/wk for 16 wk)
Trial: 25593015
Drug: Cetuximab 400mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab 400mg/m² IV on day 1 followed by 250mg/m² IV weekly (Arm A)
Trial: 25593015
Drug: Cetuximab 400mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab 400mg/m² IV on day 1 followed by 250mg/m² IV weekly plus sorafenib 400mg PO twice-a-day (Arm B)
Trial: 23826087
Drug: Intralesional meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional meglumine antimoniate (i.l.MA)
Trial: 23826087
Drug: Intralesional meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional meglumine antimoniate (i.l.MA) + non-silver dressing
Trial: 23826087
Drug: Intralesional meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional meglumine antimoniate (i.l.MA) + silver dressing
Trial: 15596636
Drug: Nifedipine gastrointestinal
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine gastrointestinal therapeutic system, 30 mg/d
Trial: 15596636
Drug: Hydrochlorothiazide-amiloride (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide-amiloride (25 mg/d of hydrochlorothiazide and 2.5 mg/d of amiloride hydrochloride)
Trial: 15596636
Drug: Low creatinine
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low creatinine clearance (<60 mL/min)
Trial: 11387278
Drug: Semen collection
RxNorm normalized name: Hippocastani semen
DrugBank: Horse chestnut (DB13195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semen collection into 20 ml HEPES buffered Ham's F‐10 medium with 10% human serum albumin (group B)
Trial: 3595971
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 1 mg of ONO-802 vaginal suppository every 3 hours (maximum of five suppositories)
Trial: 3595971
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 1 mg of ONO-802 vaginal suppository (maximum of three suppositories)
Trial: 30993934
Drug: Diabetic rabbits
RxNorm normalized name: Rabbit
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic rabbits with contrast agent (DCA)
Trial: 30993934
Drug: Healthy rabbits
RxNorm normalized name: Rabbit
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy rabbits with contrast agent (NCA)
Trial: 21598886
Drug: Closed reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed reduction (conservative treatment)
Trial: 15570082
Drug: Bortezomib at
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib at 1.2 mg/m2/dose
Trial: 15570082
Drug: Bortezomib at
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib at 1.6 mg/m2/dose
Trial: 9549633
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg d-sotalol
Trial: 9549633
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg d-sotalol
Trial: 9549633
Drug: 3.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg/kg d-sotalol
Trial: 8368471
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefamandole administered preoperatively
Trial: 8368471
Drug: Additional administration
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional administration of 1 g cefamandole before cardiopulmonary bypass
Trial: 29180524
Drug: Omadacycline 300
RxNorm normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omadacycline 300 mg